Suppr超能文献

乳酸脱氢酶与绝对淋巴细胞计数比值及白蛋白与纤维蛋白原比值对弥漫性大 B 细胞淋巴瘤的预后价值。

Prognostic value of lactate dehydrogenase to absolute lymphocyte count ratio and albumin to fibrinogen ratio in diffuse large B-cell lymphoma.

机构信息

Department of Thoracic Medical Oncology, Tongling People's Hospital, Tongling, Anhui Province, P.R. China.

Department of Medical Oncology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, P.R. China.

出版信息

Medicine (Baltimore). 2024 Jul 26;103(30):e39097. doi: 10.1097/MD.0000000000039097.

Abstract

With the continuous improvement of treatment strategy, the prognostic value of international prognostic index (IPI) alone is limited for diffuse large B-cell lymphoma (DLBCL). Our study aims to explore the effect of lactate dehydrogenase (LDH)to absolute lymphocyte count (ALC) ratio (LAR) and albumin to fibrinogen ratio (AFR) on the prognosis of patients with DLBCL. The venous blood LDH, ALC, albumin and fibrinogen within 1 week before the first chemotherapy in 74 DLBCL patients were collected to calculate the LAR and AFR values. The impact of LAR and AFR on the progression-free survival (PFS) of patients with DLBCL was studied by the survival analysis. The area under the receiver operating characteristic curve (AUC) and concordance index (C-index) were used to analyze the predictive efficiency of each model for the PFS of DLBCL patients. Cox univariate analysis suggested that elevated LAR (P < .001) and decreased AFR (P < .001) were risk factors for PFS in DLBCL patients. Multivariate analysis revealed that LAR (P < .001) and AFR (P = .004) were 2 independent prognostic parameters. The AUC values of IPI, AFR + IPI, LAR + IPI and AFR + LAR + IPI to predict the PFS of DLBCL patients were 0.806 (95%CI 0.707-0.905, P < .001), 0.839 (95%CI 0.747-0.932, P < .001), 0.851 (95%CI 0.764-0.938, P < .001), and 0.869 (95%CI 0.787-0.952, P < .001), respectively. The C-index values of above 4 models were 0.802 (95%CI 0.629-0.975, P < .001), 0.842 (95% CI 0.735-0.949, P < .001), 0.846 (95%CI 0.716-0.976, P < .001), and 0.864 (95%CI 0.781-0.941, P < .001), respectively. The results suggest that both LAR and AFR are independent prognostic factors for PFS in DLBCL patients. Furthermore, their combination with IPI has better predictive efficiency for the prognosis of DLBCL patients.

摘要

随着治疗策略的不断改进,国际预后指数(IPI)单独对弥漫性大 B 细胞淋巴瘤(DLBCL)的预后价值有限。我们的研究旨在探讨乳酸脱氢酶(LDH)与绝对淋巴细胞计数(ALC)比值(LAR)和白蛋白与纤维蛋白原比值(AFR)对 DLBCL 患者预后的影响。收集 74 例 DLBCL 患者首次化疗前 1 周内的静脉血 LDH、ALC、白蛋白和纤维蛋白原,计算 LAR 和 AFR 值。通过生存分析研究 LAR 和 AFR 对 DLBCL 患者无进展生存期(PFS)的影响。采用受试者工作特征曲线(ROC)下面积(AUC)和一致性指数(C-index)分析各模型对 DLBCL 患者 PFS 的预测效率。Cox 单因素分析提示,升高的 LAR(P<0.001)和降低的 AFR(P<0.001)是 DLBCL 患者 PFS 的危险因素。多因素分析显示,LAR(P<0.001)和 AFR(P=0.004)是 2 个独立的预后参数。IPI、AFR+IPI、LAR+IPI 和 AFR+LAR+IPI 预测 DLBCL 患者 PFS 的 AUC 值分别为 0.806(95%CI 0.707-0.905,P<0.001)、0.839(95%CI 0.747-0.932,P<0.001)、0.851(95%CI 0.764-0.938,P<0.001)和 0.869(95%CI 0.787-0.952,P<0.001)。上述 4 个模型的 C-index 值分别为 0.802(95%CI 0.629-0.975,P<0.001)、0.842(95%CI 0.735-0.949,P<0.001)、0.846(95%CI 0.716-0.976,P<0.001)和 0.864(95%CI 0.781-0.941,P<0.001)。结果表明,LAR 和 AFR 均是 DLBCL 患者 PFS 的独立预后因素。此外,它们与 IPI 的联合对 DLBCL 患者的预后具有更好的预测效能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9ed2/11272371/7904d302731a/medi-103-e39097-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验